Since first-generation GLP-1 aids weight loss by mildly reducing appetite, the Points Program is recommended for people taking those medications
Sandy Van, Obesity Medicine Specialist and Chief Medical Officer, Hims & Hers Canada
The products listed on this page are intended solely for research use only (RUO)
Table of Contents Why Saxenda May Not Suppress Your Appetite as Expected Saxenda (liraglutide 3.0 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for weight management in adults with a body mass index (BMI) of 30 kg/m or greater, or 27 kg/m or greater with weight-related comorbidities
Additionally, carnitine promotes muscular growth by assisting in the metabolism of fatty acids and promotes recovery after intense physical activity
While there have been several other weight loss medications, programs, diets, and surgical procedures available, some people still struggle with their weight with no help from these available sources